Clinical Trials
5 trialsNCT01147484 2023-08-04
IND197
Canadian Cancer Trials Group
Phase 2 Completed
NCT00726323 2017-12-11
A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)
GlaxoSmithKline
Phase 2 Completed
NCT00725764 2017-10-16
Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck
GlaxoSmithKline
Phase 2 Completed
NCT00725712 2017-08-24
Study of GSK1363089 in Metastatic Gastric Cancer
GlaxoSmithKline
Phase 2 Completed
NCT02034097 2014-05-19
A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer
GlaxoSmithKline
Phase 2 Withdrawn